- Home
- SLRX vs BJDX Comparison
SLRX vs BJDX Comparison
Compare SLRX & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLRX | BJDX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLRX | BJDX |
|---|---|---|
| Price | $0.67 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 388.9K | 123.7K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $55.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $0.78 |
| 52 Week High | $108.00 | $10.20 |
Technical Indicators
Market Signals| Indicator | SLRX | BJDX |
|---|---|---|
| Relative Strength Index (RSI) | 25.17 | 21.08 |
| Support Level | $0.64 | $1.13 |
| Resistance Level | $0.72 | $1.10 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 7.49 | 8.23 |
Price Performance
Historical ComparisonAbout SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.